Wilson Disease (WD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Wilson Disease (WD) is an inherited disorder of copper metabolism. The disease is caused by homozygous or compounds heterozygous mutations (the presence of two different mutant alleles) in ATP7B, which encodes transmembrane copper-transporting ATPase 2 (widely known as ATP7B), which mediates the excretion of copper into bile and delivers copper for the functional synthesis of ceruloplasmin (the major copper-transporting protein in the blood) diagnostic methods, ideal treatment regimens, efficacy evaluation standards and prognostic indicators for NPC. The liver is the site of metabolism for dietary copper; in WD, defective ATP7B function leads to copper overload in hepatocytes, which is associated with liver pathology.
·
Wilson disease (WD) prevalence ranges between
31 to 37 cases per 1,00,000 individuals in EU countries, 48 to 59 cases in the
USA, and 33 cases per 1,000,000 individuals in Japan.
·
The global prevalence of WD was estimated to
range between 1/30,000 to 1/10,000 individuals in non-isolated populations,
with a mutation carrier frequency.
Thelansis’s “Wilson Disease (WD)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Wilson
Disease (WD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Wilson Disease (WD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Wilson Disease (WD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment